Published
3 years agoon
Germany-based BioNTech is working with Pfizer Inc. to develop a potential COVID-19 vaccine. The collaboration aims to accelerate the development of BioNTech’s potential COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April.
At the beginning of 2019, as evidence of the danger of a COVID-19 pandemic was growing, we initiated an internal R&D effort to develop a vaccine to induce immunity and prevent the COVID-19 infection. We named our internal efforts “Project Lightspeed.”
The resulting product candidate, BNT162, is a potential first-in-class mRNA vaccine against COVID-19.
The next step in the development process is to initiate clinical testing for BNT162, pending approval from the regulatory agencies, as part of a global clinical development program in Europe, the United States, and China.
We are accelerating operational plans to manufacture the vaccine for clinical trials along with our partner, Polymun, at our state-of-the-art GMP-certified mRNA manufacturing facilities in Europe.
We are committed to working as quickly as possible internally and with our partners to advance BTN162 with the goal of saving lives. That means we will continue to follow the regulatory guidelines and rules to ensure a safe and effective vaccine.
Ambulances, Hospitals for Real Medical Emergencies Only, Fresno Officials Say
COVID-19 Has Dramatically Lowered the Life Expectancy of Californians
Behind on Your Mortgage Payment? The State Can Help
Get COVID Tested and Treated in Same Fresno Visit
Fresno County Health Warns of Rising Flu and COVID Cases
Two Years into the Pandemic, Fresno Renters and Landlords Await Promised Aid